J&J To Seek Remicade Rights Amid Pending Schering-Plough/Merck Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck and Schering argue the merger does not constitute “change of control” for Remicade and Simponi under initial J&J agreement.
You may also be interested in...
Merck And J&J Settle Remicade Dispute By Redrawing The Map
Johnson & Johnson Inc. and Merck & Co. Inc. settled their two-year dispute over Remicade (infliximab) and its successor Simponi (golimumab) April 15, avoiding an arbitrator's decision by striking a revised agreement under which each will retain some territorial rights to the drugs
Merck And J&J Settle Remicade Dispute By Redrawing The Map
Rather than let an arbitration panel decide the fate of two anti-TNF drugs, Merck surrenders many territories but holds onto Europe.
Merck And J&J Settle Remicade Dispute By Redrawing The Map
Rather than let an arbitration panel decide the fate of two anti-TNF drugs, Merck surrenders many territories but holds onto Europe.